William Blair & Company
SUPN icon

William Blair & Company’s Supernus Pharmaceuticals SUPN Stock Holding History

William Blair & Company’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-440
Closed -$14K – 1939
2021
Q2 		$14K Sell
440
-150
-25% -$4.6K ﹤0.01% 1799
2021
Q1 		$15K Buy
590
+115
+24% +$3.22K ﹤0.01% 1769
2020
Q4 		$12K Buy
475
+50
+12% +$1.08K ﹤0.01% 1735
2020
Q3 		$9K Buy
425
+135
+47% +$3.06K ﹤0.01% 1637
2020
Q2 		$7K Sell
290
-235
-45% -$5.19K ﹤0.01% 1612
2020
Q1 		$9K Sell
525
-1,150
-69% -$24.2K ﹤0.01% 1567
2019
Q4 		$40K Buy
+1,675
New +$40.7K ﹤0.01% 1513
2018
Q1 		– Sell
-11,171
Closed -$445K – 1586
2017
Q4 		$445K Buy
11,171
+4,161
+59% +$164K ﹤0.01% 1000
2017
Q3 		$280K Buy
+7,010
New +$303K ﹤0.01% 1136

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

William Blair & Company's SUPN Position: Q3 2021 in Review

William Blair & Company sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 440 shares — an estimated $14K sold.

William Blair & Company first reported a position in SUPN in Q3 2017 and held it in 9 quarters. The position peaked at $445K in Q4 2017. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

  • William Blair & Company reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • William Blair & Company sold 440 Supernus Pharmaceuticals shares in Q3 2021, an estimated $14K.
  • William Blair & Company first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 9 quarters.
  • William Blair & Company's Supernus Pharmaceuticals position peaked at $445K in Q4 2017.
  • 223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on William Blair & Company's 13F filing for Q3 2021, filed 12 Nov 2021.